| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 3,000 | 2,450 | 380 | 500 | 0 |
| Sales Growth | +22.45% | +544.74% | -24.00% | unch | unch |
| Net Income | 39,790 | -64,180 | -88,980 | -50,350 | -34,280 |
| Net Income Growth | +162.00% | +27.87% | -76.72% | -46.88% | -108.26% |
Pavmed Inc
(PAVM)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation and cardiovascular intervention. PAVmed Inc. is headquartered in New York City.
Fiscal Year End Date: 12/31